Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $43.60 Consensus Target Price from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $38.00.

Several brokerages have recently issued reports on INO. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. HC Wainwright decreased their target price on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday. Finally, Oppenheimer dropped their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $4.06 on Friday. Inovio Pharmaceuticals has a 1-year low of $3.85 and a 1-year high of $14.75. The stock has a fifty day simple moving average of $5.61 and a two-hundred day simple moving average of $8.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of Inovio Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the last quarter. State Street Corp boosted its position in shares of Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after purchasing an additional 51,414 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at approximately $661,000. Dimensional Fund Advisors LP acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth $605,000. Finally, Wellington Management Group LLP acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter valued at $379,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.